MIRA Pharmaceuticals (NASDAQ:MIRA) | WebDisclosure

Basculer en Français

10719	Companies
229678	Keywords
158204	Articles
121982	Press releases

Home
Companies
MIRA Pharmaceuticals

PRESS RELEASE

published on 08/19/2025 at 14:30, 10 months 26 days ago

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage
MIRA Pharmaceuticals, Inc. announces successful completion of Phase 1 Single Ascending Dose trial for oral Ketamir-2, preparing for U.S. Phase 2a trial in Q4 2025

Clinical Trial Phase 1 MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain
BRIEF

published on 08/12/2025 at 14:35, 11 months 2 days ago

MIRA Pharmaceuticals développe le kétamir-2 pour le traitement de la douleur neuropathique

Essais Cliniques Croissance Du Marché Médicaments Ketamir-2 Douleur Neuropathique
BRIEF

published on 08/12/2025 at 14:35, 11 months 2 days ago

MIRA Pharmaceuticals Advances Ketamir-2 for Neuropathic Pain Treatment

Pharmaceuticals Clinical Trials Market Growth Ketamir-2 Neuropathic Pain
PRESS RELEASE

published on 08/12/2025 at 14:30, 11 months 2 days ago

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
MIRA Pharmaceuticals announces the acceptance of a manuscript in Frontiers in Pharmacology detailing Ketamir-2's efficacy in neuropathic pain, supporting Phase 2a trials by 2025

Clinical Trials MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Pharmacology
BRIEF

published on 07/30/2025 at 13:35, 11 months 15 days ago

Le kétamir-2 topique de MIRA Pharmaceuticals est comparable à la morphine injectée dans une étude sur la douleur

Soulagement De La Douleur Étude Préclinique Kétamir-2 Topique Comparaison De La Morphine Traitement Localisé
BRIEF

published on 07/30/2025 at 13:35, 11 months 15 days ago

MIRA Pharmaceuticals' Topical Ketamir-2 Matches Injected Morphine in Pain Study

Preclinical Study Pain Relief Topical Ketamir-2 Morphine Comparison Localized Treatment
PRESS RELEASE

published on 07/30/2025 at 13:30, 11 months 15 days ago

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study
MIRA Pharmaceuticals announces new preclinical data showing topical Ketamir-2 provides effective pain relief comparable to injected morphine in animal models. The treatment has potential for both centralized and localized pain pathways

Preclinical Data MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Topical Pain Relief
BRIEF

published on 07/29/2025 at 13:35, 11 months 16 days ago

MIRA Pharmaceuticals reçoit le feu vert de la FDA pour les essais du kétamir-2

Autorisation De La FDA Expansion Stratégique Ketamir-2 Douleur Neuropathique Essai De Phase 1
BRIEF

published on 07/29/2025 at 13:35, 11 months 16 days ago

MIRA Pharmaceuticals Receives FDA Green Light for Ketamir-2 Trials

FDA Clearance Phase 1 Trial Strategic Expansion Ketamir-2 Neuropathic Pain
PRESS RELEASE

published on 07/29/2025 at 13:30, 11 months 16 days ago

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain
MIRA Pharmaceuticals advances non-opioid oral drug Ketamir-2 for neuropathic pain, clears FDA IND for Phase 2a, demonstrates potent effects in preclinical studies

FDA Preclinical Studies MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain

Accesswire

Published on 07/15/2026 at 00:55, 43 minutes ago

Arctic Fox Announces Name Change
Published on 07/14/2026 at 22:30, 3 hours 8 minutes ago

Hillcrest Energy Technologies Announces Board and Leadership Changes Following 2026 Annual General Meeting
Published on 07/14/2026 at 22:30, 3 hours 8 minutes ago

Loop Industries Reports First Quarter Fiscal 2027 Results and Provides Update on Progress Towards Commercialization
Published on 07/14/2026 at 16:40, 8 hours 58 minutes ago

AIAI Holdings' MediGuide Enters the State-of-the-Art Medicine Market With AI-Driven Innovation
Published on 07/14/2026 at 15:45, 9 hours 53 minutes ago

Silver Storm Commences Hot Commissioning of the La Parrilla Sulphide Circuit, Amends the Samsung Prepayment Agreement, and Secures US$5 Million Loan from First Majestic

View all ACCESSWIRE

EQS Group

Published on 07/14/2026 at 23:48, 1 hour 50 minutes ago

North Peak Announces Proposed Extension of Warrant Expiry Date
Published on 07/14/2026 at 19:14, 6 hours 24 minutes ago

EQS-Adhoc: Nagarro SE: BaFin Enforcement Review of the 2022 Consolidated Financial Statements
Published on 07/14/2026 at 18:17, 7 hours 21 minutes ago

EQS-Adhoc: Delivery Hero confirms advanced negotiations with Uber Technologies in respect to potential takeover offer
Published on 07/14/2026 at 17:51, 7 hours 46 minutes ago

Aumann announces share buyback with an allotment ratio of approximately 6%
Published on 07/14/2026 at 17:30, 8 hours 8 minutes ago

NABR: The U.S. Fish and Wildlife Service for the Second Time Rejects Activists' Petition to List Long-Tailed Macaque Monkeys Under the Endangered Species Act

Les Echos

Published on 07/13/2026 at 18:00, 1 day 7 hours ago

CP Icade - Icade reprend 100% de la propriété de la Tour Eqho à la Défense
Published on 07/13/2026 at 18:00, 1 day 7 hours ago

PR Icade - Icade regains full ownership of the Eqho Tower in La Défense
Published on 07/13/2026 at 18:00, 1 day 7 hours ago

THERMADOR GROUPE : 2026 half-year turnover
Published on 07/13/2026 at 18:00, 1 day 7 hours ago

THERMADOR GROUPE : publication du chiffre d'affaires semestriel 2026
Published on 07/13/2026 at 17:45, 1 day 7 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE